レステノシスを超えて:第2世代の冠動脈ステント試験の5年間の臨床結果
Donald E Cutlip1, Amit G Chhabra, Donald S Baim
1Harvard Clinical Research Institute, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. dcutlip@hcri.harvard.edu
Circulation
|September 1, 2004
まとめ
冠動脈ステントの植え付け後,遅い臨床失敗は,主にステントされた病変のレステノシスではなく,他の冠動脈の疾患進行によって引き起こされます. 糖尿病と多血管性疾患は,レステノーシスおよび非レステノーシスイベントの両方のリスクを高めます.
科学分野:
- 心血管医学 心血管医学
- 介入性心臓病学 介入性心臓病学
- クリニック・トライアル 臨床試験
背景:
- 冠動脈ステントの植え付けは,冠動脈疾患の後の結果を改善することを目的としています.
- ステント挿入後の早期の臨床不全は,手続上の問題と再緊張症に関連しています.
- 病気の進行と比較して,レステノーシスからの長期的な失敗の貢献は不明のままです.
研究 の 目的:
- 冠動脈ステントの植え付け後の長期的な臨床イベントの発生率を調査する.
- 標的の損傷イベント (レステノス) と非標的の損傷イベント (疾患進行) を区別する.
- ステント移植後の遅い臨床失敗の危険因子を特定する.
主な方法:
- 第2世代の冠動脈ステント試験の1228人の患者を分析し,5年間追跡した.
- 標的病変または非標的病変として分類され,さらに手順的,再発性,または非再発性として分類される臨床的イベント.
- 危険度や独立したリスク要因を特定するための統計分析.
主要な成果:
- 1年目のターゲット・レシオンの発生率は18.3%で,非ターゲット・レシオンの発生率は12.4%でした.
- 1年目以降,年間ターゲット・レシオンの発生率は1.7%に低下し,非ターゲット・レシオンの発生率は6.3%に増加した.
- 5年目には累積レステノシスが20.3%,非レステノシスが37.9%で,合計率は46.4%でした. 糖尿病と多血管性疾患は,独立した危険因子であった.
結論:
- ステントを挿入してから1年を超えると,臨床結果は主にステントを挿入していないセグメントにおける疾患進行によって影響されます.
- ステント付の病変そのものは,遅い臨床的イベントを引き起こすという点で相対的な安定性を示しています.
- 他の冠動脈における疾患の進行は,ステントを設置した後,長期的に重大なリスクをもたらす.
関連する概念動画
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...


